News stories about Thermo Fisher Scientific (NYSE:TMO) have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Thermo Fisher Scientific earned a news impact score of 3.83 on their scale. InfoTrie also gave media coverage about the medical research company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Thermo Fisher Scientific’s score:
- Cerner (CERN) Earnings Beat Estimates in Q3, Improve Y/Y (finance.yahoo.com)
- Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View (finance.yahoo.com)
- Thermo Fisher Scientific continues strong year (wfmz.com)
- Thermo Fisher Scientific (NYSE:TMO) Releases Earnings Results, Beats Expectations By $0.06 EPS (americanbankingnews.com)
- Edited Transcript of TMO earnings conference call or presentation 23-Oct-19 12:30pm GMT (finance.yahoo.com)
Thermo Fisher Scientific stock opened at $296.68 on Friday. Thermo Fisher Scientific has a 12-month low of $208.34 and a 12-month high of $305.45. The stock has a market capitalization of $118.91 billion, a P/E ratio of 26.68, a P/E/G ratio of 1.93 and a beta of 1.13. The firm’s 50-day moving average is $289.03 and its two-hundred day moving average is $281.75. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.80 and a quick ratio of 1.07.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The company had revenue of $6.27 billion for the quarter, compared to analysts’ expectations of $6.19 billion. During the same period last year, the company earned $2.62 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. As a group, analysts forecast that Thermo Fisher Scientific will post 12.32 EPS for the current year.
A number of brokerages recently commented on TMO. ValuEngine cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Credit Suisse Group reissued a “buy” rating and issued a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC raised their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $314.45.
In other news, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $272.93, for a total transaction of $500,280.69. Following the transaction, the director now directly owns 28,592 shares in the company, valued at approximately $7,803,614.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the transaction, the chief executive officer now owns 342,193 shares in the company, valued at $97,466,832.19. The disclosure for this sale can be found here. Insiders have sold a total of 54,104 shares of company stock worth $15,418,539 over the last ninety days. 0.45% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.